Service Communautaire d'Information sur la Recherche et le Développement - CORDIS

FP6

EUROPEAN MCL NETWORK Résumé de rapport

Project ID: 503351
Financé au titre de: FP6-LIFESCIHEALTH

Final Report Summary - EUROPEAN MCL NETWORK (European Mantle Cell Lymphoma Network: Translational determination of molecular prognostic factors and pharmacogenomics)

Mantle cell lymphoma (MCL) is a distinct, clinically very aggressive subentity of malignant lymphoma with a median survival of three years. However, a small subset of patients represents long-term survivors. So far, the discriminative power of different prognostic parameters has been limited and does not allow the reliable identification of the individual patient's risk profile.

Thus, a better understanding of the underlying molecular mechanisms is eagerly warranted. In the previous few years, European-wide MCL networks of clinicians (European MCL clinical intergroup), pathologists (European MCL Pathology Panel) and basic researchers (European MCL Research Network) were established to investigate the clinical as well as molecular aspects of malignant transformation and progression in MCL.

Based on these extensive prerequisites and the recent development of innovative molecular techniques (matrix comparative genomic hybridisation (CGH), ribonucleic acid (RNA) array chips, real-time quantitative polymerase chain reaction (RQ-PCR), proteomics), partners adopted a global approach to investigate innovative treatment options of MCL and evaluate new predictive (pharmacogenomics, minimal residual disease) and prognostic molecular markers (genomic alterations, ribonucleic acid (RNA)/proteome profiles).

In addition, patient samples for the systematic evaluation of MRD was successfully collected and analysed for the vast majority of these study cases. Finally, molecular results of extensive RNA array, PCR and proteome analyses not only indicated more individualised therapeutic strategies based on the molecular risk profile, but were expected to finally elucidate the way to future molecular targeted treatment options in a subtype of malignant lymphoma with an otherwise dismal clinical outcome.

Informations connexes

Contact

Wolfgang, Martin HIDDEMANN, DREYLING, (Director, Assistent Professor)
Tél.: +49-897095-2202
Fax: +49-897095-2201